StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Could be Valued at $42B Cash in Samsung Deal, Here Are Key Questions According to Truist Securities
December 29, 2021 5:01 PM
Truist analyst Robyn Karnauskas reiterates a "Buy" rating and $502 price target on shares of Biogen (NASDAQ: BIIB), following rumors ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Hot Comments
Momentum Movers
Trader Talk
Next Articles
Samsung BioLogics Said Biogen (BIIB) Buyout Rumor 'Untrue'
December 29, 2021 11:59 PM
Samsung BioLogics says report on Biogen deal talks untrue
December 29, 2021 2:50 PM
Biogen (BIIB) said it does not comment on market rumors or speculation
December 29, 2021 2:30 PM
Biogen (BIIB) December weekly calls active after Korea Economic Daily report of buyout talks
December 29, 2021 2:30 PM
Biogen (BIIB) option implied volatility increases after Korea Economic Daily report of buyout talks
December 29, 2021 2:29 PM
Biogen (BIIB) call put ratio 2.1 calls to 1 put as shares rally 9.5%
December 29, 2021 2:27 PM
Biogen (BIIB) Spikes Higher on Rumor
December 29, 2021 2:12 PM
Samsung Group in talks to buy Biogen (BIIB) - Korean Economic Daily
December 29, 2021 2:10 PM
Biogen (BIIB) PT Lowered to $350 at Oppenheimer
December 27, 2021 4:57 AM
